Heart & Cardiovascular
Team that developed leading cardiovascular stent graft, first percutaneous heart valve and first heart stem cell therapy has developed 8 cardiovascular and heart-related organ regeneration startups. Second Heart Assist expects to complete first-in-man study in 30 pts by spring and to exit. Only competitor on USA market now reached $21 billion valuation this year. Vascustim is entering U.S. clinical studies for diabetic ulcer treatment. PressureStim is planning clinical studies for blood pressure management in China. AortaCell is ready to launch aorta regeneration studies at U Virginia – core team previously captured world leadership in endovascular aorta repair. BioLeonhardt completed a small animal study at U of Utah and is now moving to large animal studies at Texas Heart Institute for total heart regeneration.

Cosmetic & Personal Care
7 startups all at clinical stage of development. MyoStim ED published first study this summer with 85% success compared to 0% for placebo group in treating erectile dysfunction. A new study with more signals is underway with target of 100% in target treatment group. HairCell launched clinical trials in South Africa targeting 30% improvement of hair density. Samumed a San Diego based competitor reached $12 billion valuation for 10% hair density improvement. TestiStim has patent issued and pilot data for testosterone management. SkinStim launched clinical trials in the USA and has interested acquirer already. DentaCell has data from numerous centers and is developing a full product pipeline. OrthodontiCell believes it can reduce time for straightening teeth by 2/3rds and his clinical trials now. Align Technology the leading competitor reached $30.9 billion valuation this year. Stem Cell Bra is launching clinical trials in South Africa after achieving 20% to 30% breast fullness volume increase in 4 weeks of treatment in large animals. At least 3 exits are expected in 2019.

HEART AND CARDIOVASCULAR
> BioLeonhardt – heart regeneration = $1,000,000
> AortaCell – aorta regeneration – $400,000
> BioPace – biological pacemaker regeneration – $300,000
> Valvublator – heart valve decalcification and regeneration – $700,000
> VibroCell CoroStim– vibrational energy to prevent clots, plaque, calcification – $400,000
> Vascustim (formerly MyoStim Peripheral)– limb blood flow improvement – $300,000
> Second Heart Assist, Inc. – circulatory assist pumps – $2,300,000
> PressureStim – bioelectric blood pressure control – $600,000

Major Organ Regeneration
> EyeCell – eye regeneration – $200,000
> PancreaCell – pancreas regeneration – $200,000
> RegenaLung – lung regeneration – $100,000
> LiverCell – liver regeneration – $200,000
> KidneyCell – kidney regeneration – $200,000
> EarCell – ear hearing regeneration – $100,000
> BladderCell – bladder regeneration – $200,000
> InStim – bioelectric inflammation management – $300,000
>. OrthoStim – bioelectric and biologics joint recovery – $200,000
> BioLeonhardt Whole Body Regeneration – Whole body regeneration – $300,000

Important Links

> https://leonhardtventures.com/our-companies/

> https://leonhardtventures.com/2018-elevator-pitches/

> https://leonhardtventures.com/2018-annual-report/

> https://app.slidebean.com/p/JUUCe06oiB/Leonhardts-Launchpads-2019-Shareholder-Meeting-Slide-Deck

> https://leonhardtventures.com/development-pipeline/

> https://leonhardtventures.com/regenerative-medtech/

> https://leonhardtventures.com/frequently-asked-questions/

Valuations > https://leonhardtventures.com/valuations/

Email us at howard@leonhardtventures.com for Password